Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs and does not recommend treatment solutions (if involved), nor does it represent the platform's position.Any article reprinted must be authorized.
On March 13, 2025, Frontera Therapeutics, an innovative biotechnology company in China, announced that its self-developed recombinant adeno-associated virus (rAAV) gene therapy product FT-003 Injection has once again received tacit approval for clinical trials from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. The product is intended for the treatment of Diabetic Retinopathy (DR). The DR indication follows nAMD and DME.The Third New Indication Approval for FT-003 Injection.
FT-003 Injection: Early Data Validates Its Clinical Value- Significant Efficacy: Patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) who received FT-003 injection showed a marked improvement in vision and retinal structure, with a significant reduction in the need for anti-VEGF treatments. Patients under the longest follow-up of two years did not require anti-VEGF treatment during this period, greatly reducing the treatment burden on patients.
- High Safety: Through the company's innovative vector optimization design platform and production processes, FT-003 has demonstrated good safety and tolerability in clinical trials.
Global Layout Accelerates, Multiple Indications Advance SynergisticallyFT-003, as a core pipeline product of Frontera Therapeutics, has previously been approved to conduct Phase II clinical trials for nAMD and DME in both China and the United States. The trial has already been initiated in multiple hospitals across China, with patient recruitment underway.About Diabetic Retinopathy (DR)The approval of the new DR indication marks the company's strategic extension in the field of fundus diseases. Diabetic Retinopathy (DR) is one of the leading causes of vision loss and blindness globally, with approximately 30-35% of diabetic patients progressing to DR, among which 10% develop vision-threatening lesions. In China, about 19.5 million diabetic patients have DR. Depending on the severity of the condition, current treatments include laser therapy, anti-VEGF drugs, and vitreous surgery, with early intervention being key to preventing vision loss. Compared to other therapies, anti-VEGF drug therapy can provide intervention at all stages of DR and effectively maintain the anatomical structure of the retina, inhibit intraocular neovascularization, and offer therapeutic benefits. However, current anti-VEGF drugs require repeated injections for sustained treatment, which not only increases the treatment burden on patients but also reduces patient compliance. Therefore, there is an urgent clinical need for new treatment options to meet the long-term treatment needs of DR patients.The core challenge of gene therapy lies in precise delivery and long-term effectiveness. FT-003 has demonstrated good delivery efficiency and effectiveness through intravitreal injection. The company will continue to explore the therapeutic potential of FT-003 and its application potential in other ophthalmic diseases, providing better solutions for patients worldwide.Source: Frontera Therapeutics
